|
|
Research progress on rabies treatment methods and application of antiviral drugs |
LIU Qian1,2, ZHU Wu-yang1,2 |
1. Key Laboratory of Biosafety, National Health and Family Planning Commission, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 2. Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430000, China |
|
|
Abstract Rabies is a severe zoonosis caused by rabies virus, which is mainly characterized by the invasion of the central nervous system. Its mortality rate is almost 100%. Although timely and standardized pre-exposure and post-exposure treatment can effectively prevent rabies, there are no effective treatments and antiviral drugs for rabies. With the in-depth study of molecular pathogenic mechanism of rabies virus, people have conducted a series of explorations on rabies treatment methods and anti-rabies virus drugs. This article reviews the advances on the rabies treatment and antiviral drugs.
|
Received: 18 March 2020
|
|
Fund:Supported by the National Science and Technology Major Project (No.2018ZX10201002, No.2018ZX10734401) |
Corresponding Authors:
Zhu Wu-yang,Email: zhuwuyang1971@sina.com
|
|
|
|
[1] Willoughby RE, Jr Tieves KS, Hoffman GM, et al.Survival after treatment of rabies with induction of coma[J]. N Engl J Med, 2005,352(24):2508-2514. DOI: 10.1056/NEJMoa050382 [2] Vigerelli H, Sciani JM, Pereira PMC, et al.Bufotenine, a tryptophan-derived alkaloid, suppresses the symptoms and increases the survival rate of rabies-infected mice: the development of a pharmacological approach for rabies treatment[J]. J Venom Anim Toxins Incl Trop Dis, 2020, 26:e20190050. DOI: 10.1590/1678-9199-JVATITD-2019-0050 [3] Poston R, Hill R, Allen C, et al.Achieving scientific and regulatory success in implementing non-animal approaches to human and veterinary rabies vaccine testing: A NICEATM and IABS workshop report[J]. Biologicals, 2019, 60:8-14. DOI: 10.1016/j.biologicals.2019.06.005 [4] Jackson AC.Recovery from rabies: a call to arms[J]. J Neurol Sci, 2014, 339(1/2): 5-7. DOI: 10.1016/j.jns.2014.02.012 [5] Mader EC, Jr Maury JS, Santana-Gould L, et al.Human rabies with initial manifestations that mimic acute brachial neuritis and guillain-barre syndrome[J]. Clin Med Insights Case Rep, 2012, 5:49-55. DOI: 10.4137/CCRep.S9318 [6] Ackerknecht EH.On the history of rabies[J]. Schweiz Med Wochenschr, 1966, 96(23): 746-748. [7] Symposium on rabies and brucellosis in Mediterranean countries and the Arab peninsula. Montpellier, 4-6 November 1985. Abstracts[J]. Comp Immunol Microbiol Infect Dis, 1986, 9(1): 1-11. DOI:10.1016/0147-9571(86)90051-2 [8] Baron S.Introduction to Virology[M]. Galveston (TX):University of Texas Medical Branch,1996:1-14. [9] Dube C, Sanchez J, Reeves A.Adapting existing models of highly contagious diseases to countries other than their country of origin[J]. Rev Sci Tech, 2011, 30(2): 581-589. DOI: 10.20506/rst.30.2.2061 [10] Liu J, Wang S, Zhang Y, et al.Traditional Chinese medicine and cancer: history, present situation, and development[J]. Thorac Cancer, 2015, 6(5): 561-569. DOI: 10.1111/1759-7714.12270 [11] 张志斌, 余永燕. 20世纪下半叶北京中医医疗机构发展史略[J]. 中华医史杂志, 2005, 35(1): 11-16. [12] Knobel DL, Cleaveland S, Coleman PG, et al.Re-evaluating the burden of rabies in Africa and Asia[J]. Bull World Health Organ, 2005,83(5):360-368. [13] Jackson AC, Warrell MJ, Rupprecht CE, et al.Management of rabies in humans[J]. Clin Infect Dis, 2003, 36(1): 60-63. DOI: 10.1086/344905 [14] Jackson AC.Update on rabies diagnosis and treatment[J]. Case Rep Infect Dis, 2009, 11(4): 296-301. DOI: 10.1007/s11908-009-0044-0 [15] Neuwelt EA, Kikuchi K, Hill SA, et al.Barbiturate inhibition of lymphocyte function. Differing effects of various barbiturates used to induce coma[J]. J Neurosurg, 1982, 56(2): 254-259. DOI:10.3171/jns.1982.56.2.0254 [16] Jackson AC.Recovery from rabies[J]. N Engl J Med, 2005, 352(24): 2549-2550. DOI:10.1056/NEJMe058092 [17] Walker LM, Burton DR.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray[J]. Nat Rev Immunol, 2018, 18(5): 297-308. DOI: 10.1038/nri.2017.148 [18] Sparrow E, Torvaldsen S, Newall AT, et al.Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline[J]. Vaccine, 2019, 37(1):132-139. DOI:10.1016/j.vaccine.2018.11.004 [19] Nelson AL.Antibody fragments: hope and hype[J]. mAbs, 2010, 2(1): 77-83. DOI: 10.4161/mabs.2.1.10786 [20] Xi H, Meng X, Gu T, et al.Comparison of rabies virus protection by single chain and leucine zipper Fv fragments cocktail derived from a monoclonal antibody cocktail[J]. Mol Immunol, 2018, 101:197-202. DOI: 10.1016/j.molimm.2018.07.003 [21] De Benedictis P, Minola A, Rota Nodari E, et al.Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis[J]. EMBO Mol Med, 2016, 8(4): 407-421. DOI: 10.15252/emmm.201505986 [22] Gogtay NJ, Munshi R, Ashwath Narayana DH, et al.Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2/3, randomized, single-blind, noninferiority, controlled study[J]. Clin Infect Dis, 2018, 66(3): 387-395. DOI: 10.1093/cid/cix791 [23] Marissen WE, Kramer RA, Rice A, et al.Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis[J]. J Virol, 2005, 79(8): 4672-4678. DOI: 10.1128/JVI.79.8.4672-4678.2005 [24] Real E, Rain JC, Battaglia V, et al.Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides[J]. J Virol, 2004, 78(14): 7410-7417. DOI:10.1128/JVI.78.14.7410-7417.2004 [25] Lingappa UF, Wu X, Macieik A, et al.Host-rabies virus protein-protein interactions as druggable antiviral targets[J]. Proc Natl Acad Sci U S A, 2013, 110(10): 861-868. DOI: 10.1073/pnas.1210198110 [26] Crotty S, Maag D, Arnold JJ, et al.The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen[J]. Nat Med, 2000, 6(12): 1375-1379. DOI: 10.1038/82191 [27] Tox U, Schulte S, Heindl B, et al.Ribavirin priming in patients with chronic hepatitis C and normal ALT: a pilot study[J]. Hepatogastroenterology, 2008, 55(86-87): 1666-1670. [28] Mccormick JB, King IJ, Webb PA, et al.Lassa fever. Effective therapy with ribavirin[J]. N Engl J Med, 1986, 314(1): 20-26. DOI:10.1056/NEJM198601023140104 [29] Weisman LE.Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future[J]. Cardiovasc Hematol Agents Med Chem, 2009, 7(3): 223-233. DOI: 10.1002/ppul.21377 [30] Dru P, Bras F, Dezelee S, et al.Unusual variability of the Drosophila melanogaster ref(2)P protein which controls the multiplication of sigma rhabdovirus[J]. Genetics, 1993, 133(4): 943-954. [31] Konstantinova ID, Fateev IV, Galegov GA, et al.The arsenolysis reaction in the biotechnological method of synthesis of the ribavirin. Inhibition of reproduction of influenza A virus with the combination of ribavirin and ozeltamivir in experiments in vitro and in vivo[J]. Bioorg Khim, 2013, 39(5): 594-603. DOI:10.1134/s1068162013050099 [32] Dacheux L, Delmas O, Bourhy H.Human rabies encephalitis prevention and treatment: progress since Pasteur’s discovery[J]. Infect Disord Drug Targets, 2011, 11(3): 251-299. DOI: 10.2174/187152611795768079 [33] Baer GM, Shaddock JH, Moore SA, et al.Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine[J]. J Infect Dis, 1977, 136(2): 286-291. [34] Blanpied TA, Clarke RJ, Johnson JW.Amantadine inhibits NMDA receptors by accelerating channel closure during channel block[J]. J Neurosci, 2005, 25(13): 3312-3322. DOI: 10.1523/JNEUROSCI.4262-04.2005 [35] Conti C, Mastromarino P, Valenti P, et al.Effect of desferrioxamine B, a metal chelating agent, on rhabdovirus multiplication[J]. Boll Ist Sieroter Milan, 1990, 69(2): 431-436. [36] Mahadevan A, Ms S, Sk S.Retraction. Tracking the footprints of the rabies virus: are we any closer to decoding this elusive virus[J]. J Clin Pathol, 2008, 61(11): 1232. DOI: 10.1136/jcp.2006.045682.corr [37] Oberg B.Rational design of polymerase inhibitors as antiviral drugs[J]. Antiviral Res, 2006, 71(2/3): 90-95. DOI: 10.1016/j.antiviral.2006.05.012 [38] Furuta Y, Takahashi K, Shiraki K, et al.T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections[J]. Antiviral Res, 2009, 82(3): 95-102. DOI: 10.1016/j.antiviral.2009.02.198 [39] Kiso M, Takahashi K, Sakai-Tagawa Y, et al.T-705 (favipiravir) activity against lethal H5N1 influenza A viruses[J]. Proc Natl Acad Sci U S A, 2010, 107(2): 882-887. DOI: 10.1073/pnas.0909603107 [40] Mendenhall M, Russell A, Smee DF, et al.Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever[J]. PLoS Negl Trop Dis, 2011, 5(10): e1342. DOI: 10.1371/journal.pntd.0001342 [41] Banyard AC, Mansfield KL, Wu G, et al.Re-evaluating the effect of Favipiravir treatment on rabies virus infection[J]. Vaccine, 2019, 37(33): 4686-4693. DOI:10.1371/journal.pntd.0001342 [42] Kashman Y, Gustafson KR, Fuller RW, et al.The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum[J]. J Med Chem, 1992, 35(15): 2735-2743. DOI:10.1021/jm00093a004 [43] Zavrsnik D, Muratovic S, Makuc D, et al.Benzylidene-bis-(4-hydroxycoumarin) and benzopyrano-coumarin derivatives: synthesis, (1)H/(1)(3)C-NMR conformational and X-ray crystal structure studies and in vitro antiviral activity evaluations[J]. Molecules, 2011, 16(7): 6023-6040. DOI: 10.3390/molecules16076023 [44] Hwu JR, Kapoor M, Tsay SC, et al.Benzouracil-coumarin-arene conjugates as inhibiting agents for chikungunya virus[J]. Antiviral Res, 2015, 118:103-109. DOI: 10.1016/j.antiviral.2015.03.013 [45] 徐梦娴, 李明凯, 涂忠忠,等. 香豆素化合物体内外抗狂犬病病毒的效果[J]. 中国兽医学报, 2019, 39(2): 250-259. DOI:10.16303/j.cnki.1005-4545.2019.02.11 [46] Kang DG, Moon MK, Choi DH, et al.Vasodilatory and anti-inflammatory effects of the 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) via a nitric oxide-cGMP pathway[J]. Eur J Pharmacol, 2005, 524(1/3): 111-119. DOI: 10.1016/j.ejphar.2005.08.061 [47] Mizushina Y, Zhang J, Pugliese A, et al.Anti-cancer gallotannin penta-O-galloyl-beta-D-glucose is a nanomolar inhibitor of select mammalian DNA polymerases[J]. Biochem Pharmacol, 2010, 80(8): 1125-1132. DOI: 10.1016/j.bcp.2010.06.031 [48] Tu Z, Xu M, Zhang J, et al.Pentagalloylglucose inhibits the replication of rabies virus via mediation of the miR-455/SOCS3/STAT3/IL-6 pathway[J]. J Virol, 2019, 93(18):e00539-19. DOI: 10.1128/JVI.00539-19 [49] Hemachudha T, Ugolini G, Wacharapluesadee S, et al.Human rabies: neuropathogenesis, diagnosis, and management[J]. Lancet Neurol, 2013, 12(5): 498-513. DOI: 10.1016/S1474-4422(13)70038-3 [50] Constantine DG, Emmons RW, Woodie JD.Rabies virus in nasal mucosa of naturally infected bats[J]. Science, 1972, 175(4027): 1255-1256. DOI: 10.1126/science.175.4027.1255 [51] O’donnell LA, Rall GF.Blue moon neurovirology: the merits of studying rare CNS diseases of viral origin[J]. J Neuroimmune Pharmacol, 2010,5(3):443-455. DOI: 10.1007/s11481-010-9200-4 [52] Kaur M, Garg R, Singh S, et al.Rabies vaccines: where do we stand, where are we heading?[J]. Expert Rev Vaccines, 2015, 14(3): 369-381. DOI: 10.1586/14760584.2015.973403 [53] Huang CT, Li Z, Huang Y, et al.Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice[J]. Antiviral Res, 2014, 110:132-141. DOI: 10.1016/j.antiviral.2014.07.013 [54] Hooper DC, Phares TW, Fabis MJ, et al.The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system[J]. PLoS Negl Trop Dis, 2009, 3(10): e535. DOI: 10.1371/journal.pntd.0000535 [55] Chai Q, He WQ, Zhou M, et al.Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection[J]. J Virol, 2014, 88(9): 4698-4710. DOI: 10.1128/JVI.03149-13 [56] Zhu S, Guo C.Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential[J]. Viruses, 2016, 8(11):279. DOI: 10.3390/v8110279 [57] Al-Obaidi MMJ, Bahadoran A, Wang SM, et al.Disruption of the blood brain barrier is vital property of neurotropic viral infection of the central nervous system[J]. Acta Virol, 2018, 62(1): 16-27. DOI: 10.4149/av_2018_102 [58] Jackson AC, Kammouni W, Fernyhough P.Role of oxidative stress in rabies virus infection[J]. Adv Virus Res, 2011, 79:127-138. DOI:10.1016/B978-0-12-387040-7.00008-1 [59] Jackson AC, Kammouni W, Zherrbitskaya E, et al.Role of oxidative stress in rabies virus infection of adult mouse dorsal root ganglion neurons[J]. J Virol, 2010, 84(9): 4697-4705. DOI: 10.1128/JVI.02654-09 [60] Faber M, Li J, Kean RB, et al.Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus[J]. Proc Natl Acad Sci U S A, 2009, 106(27): 11300-11305. DOI: 10.1073/pnas.0905640106 [61] Huang Y, Chen Z, Huang J, et al.Parainfluenza virus 5 expressing the G protein of rabies virus protects mice after rabies virus infection[J]. J Virol, 2015, 89(6): 3427-3429. DOI: 10.1128/JVI.03656-14 |
|
|
|